Cargando…

Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies

The high primary resistance incidence and unavoidable secondary resistance are the major clinical obstacle to lasting long-term benefits in Non-small-cell lung cancer (NSCLC) patients treated with immunotherapy. The mechanisms of immunotherapy resistance in NSCLC are complex, mainly involving tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Suna, Yang, Haihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115980/ https://www.ncbi.nlm.nih.gov/pubmed/37090727 http://dx.doi.org/10.3389/fimmu.2023.1129465

Ejemplares similares

Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy
por: Jin, Zhicheng, et al.
Publicado: (2022)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

Mechanism and strategies of immunotherapy resistance in colorectal cancer
por: Shan, Jiqi, et al.
Publicado: (2022)

Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies
por: Shi, Tao, et al.
Publicado: (2023)

Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
por: Fang, Pinhao, et al.
Publicado: (2022)

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
por: Shi, Chunyan, et al.
Publicado: (2022)

Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer
por: Wang, Yuchang, et al.
Publicado: (2022)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer
por: Ge, Yang, et al.
Publicado: (2023)

GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer
por: Meng, Yinnan, et al.
Publicado: (2021)

Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms
por: Chandra, Janin, et al.
Publicado: (2022)

The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis
por: Ma, Jia-Chun, et al.
Publicado: (2022)

Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer
por: Zhou, Ting, et al.
Publicado: (2023)

Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report
por: Llanos, Anabella, et al.
Publicado: (2012)

Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy
por: Velez, Antonio, et al.
Publicado: (2023)

Editorial: Combinational immunotherapy of cancer: novel targets, mechanisms, and strategies
por: Nan, Yanyang, et al.
Publicado: (2023)

Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
por: Wang, Shuyue, et al.
Publicado: (2021)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
por: Li, Shumin, et al.
Publicado: (2020)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients
por: Baci, Denisa, et al.
Publicado: (2022)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
por: Shen, Jie, et al.
Publicado: (2023)

The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective
por: Liang, Shuai, et al.
Publicado: (2023)

Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
por: Guo, Xinyu, et al.
Publicado: (2023)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects
por: Cheng, Daoan, et al.
Publicado: (2023)

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Wang, Haowei, et al.
Publicado: (2022)

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Yang, Guanqun, et al.
Publicado: (2022)

Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
por: Wu, Yijun, et al.
Publicado: (2022)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
por: Jie, Chen, et al.
Publicado: (2023)

Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy
por: Lin, Liangbin, et al.
Publicado: (2019)

Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
por: Huang, Dingzhi, et al.
Publicado: (2023)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II
por: Li, Yueyi, et al.
Publicado: (2023)

Erratum: Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
Publicado: (2022)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Liu, Chengming, et al.
Publicado: (2021)

The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis
por: Chu, Xianjing, et al.
Publicado: (2022)

Editorial: Novel Strategies for Cancer Immunotherapy: Targeting Immune-Mediated Suppressive Mechanisms
por: Lafont, Virginie, et al.
Publicado: (2021)

Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy
por: Hu, Wei-Ting, et al.
Publicado: (2023)

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer
por: Chen, Dongna, et al.
Publicado: (2023)

Colorectal Cancer Immunotherapy: Options and Strategies
por: Johdi, Nor Adzimah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t8sbr6l26m2il24lghm3h70aut